Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Augusta University
The University of Texas Health Science Center at San Antonio
Duke University
Istari Oncology, Inc.
CNS Pharmaceuticals, Inc.
Philogen S.p.A.
Children's Oncology Group
Istituto Oncologico Veneto IRCCS
AbbVie
M.D. Anderson Cancer Center
Universitair Ziekenhuis Brussel
Hoffmann-La Roche
Isarna Therapeutics GmbH
Incheon St.Mary's Hospital
M.D. Anderson Cancer Center